ABSTRACT

Aim of the Review:

The 5 year estimated survival outcomes for muscle invasive bladder cancer was demonstrated at the interval of 60-70% in best series The aim of this review is to demonstrate the efficacy of neoadjuvant chemotherapy in muscle invasive bladder cancer.

New Findings:

The meta-analyses demonstrated a mean 5% contribution of cisplatin based chemotherapy regimes for the survival of these patients. Successful local treatment is crucial for this well tolerated therapy.

Conclusion:

Neoadjuvant chemotherapy enhances survival with reasonable toxicity and mortality rates.